

2024 Discovery Program: Type 2 Immunity in Health and Disease

Abstract Submission Policies and Procedures

Please read carefully.

All authors must follow the policies and procedures set forth by the American Academy of Allergy, Asthma & Immunology (AAAAI) for their abstract to be reviewed and considered for presentation at the 2024 Discovery Program: Type 2 Immunity in Health and Disease.

1.0 Abstract Submission

All abstracts must be submitted via the Discovery Program online submission site:
<https://education.aaaai.org/basicscienceabstract>

1.1) Submission Deadline.

It is the responsibility of the submitting author to ensure accuracy of content, spelling and author block (including listing order).

Abstracts must be received by **August 24, 2023, at 11:59pm Central Time**, in their final form, including the author listing. Absolutely no new abstracts or abstract changes, including author additions, name revisions or a revised listing order will be accepted after the submission deadline.

1.2) Abstract Preparation.

If accepted for presentation, the first abstract author is the individual who must present the abstract.

It is your responsibility to be sure that all contact information is accurate.

1.3) Funding.

The source of funding of the research summarized in the abstract must be disclosed at the time of submission. Abstract submitters must provide this information in the appropriate section of the online submission form. Abstract submissions should not be used as an opportunity to promote goods or services.

Please review your submission carefully to be sure all appropriate data and all authors are listed and in the correct order. Absolutely no new information or revisions will be accepted after the submission deadline of **August 24, 2023, 11:59pm Central Time.**

It is the responsibility of the submitting author to ensure accuracy of submissions.
Accepted abstracts will be displayed at the Discovery Program: Type 2 Immunity in Health and Disease exactly as submitted.

2.0 Organization of Abstract Body

2.1) Abstract Submission Format

There is an abstract submission template available for download in the [2024 Discovery Program Abstract Submission Form](#). Please download the template, complete it accordingly, and re-upload to the submission form for consideration. For further details of what is expected in a quality abstract, refer to the NIH article [How to Write a Scientific Abstract](#).

2.2) Abstract Length.

The maximum length of an abstract submitted for presentation at the 2024 AAAAI Discovery Program: Type 2 Immunity in Health and Disease is 250 words.

2.3) Figures

Figures and tables are not permitted, but a graphical abstract, in addition to the required written abstract, is optional.

2.4) Abbreviations.

The use of standard abbreviations is desirable (i.e., rbc, kg, mg). A special or unusual abbreviation should be placed in parentheses after the first appearance of the full word which it represents. Do not use periods after abbreviations or initials. Numerals rather than words should indicate numbers, except to begin sentences.

2.5) Drug Names.

Non-proprietary (generic) names are preferred and should be used in the title of the abstract. Generic drug names are not capitalized in the body of the abstract. If a proprietary drug name is used in the body of the abstract, the first letter is capitalized.

2.6) Format.

You may use your word processor's capabilities for bold, underline, italic, subscript and superscript, or use the tools provided when entering your abstract.

2.7) Review.

Abstracts will be graded by several reviewers on the following criteria: Basic science significance, Methodology and as an Overall submission.

If accepted for poster presentation, abstracts will appear at the Discovery Program: Type 2 Immunity in Health and Disease exactly as submitted, including the author listing as entered by the submission deadline of August 24, 2023 at 11:59pm Central Time.

3.0 Abstract Acceptance

3.1) Notification of Programming.

If the abstract is accepted for presentation at the 2024 AAAAI Annual Meeting, the first abstract author will be notified via email by December of 2023.

Only the first abstract author will be notified of abstract programming. Please make sure all contact information is accurate. Such notification will include: (1) Title of session for abstract presentation; (2) Date and time of session; and (3) Format of presentation (oral or poster). Abstracts scheduled for presentation will be grouped by topic.

3.2) Submission Agreement.

I agree to the following statements:

- I affirm that all research summarized by my abstract in which human subjects were used conformed to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 196; 14: 103) and met all the requirements governing informed consent of the country in which the research was performed.
- I affirm that all research summarized by my abstract in which animal subjects were used conformed with the 1991 revision of “Guiding Principles in the Care and Use of Animals” (American Psychological Association, Bethesda, MD 20814 3991).
- I understand that if accepted, this abstract becomes the property of the American Academy of Allergy, Asthma and Immunology. Ownership of submitted abstract not accepted for presentation reverts to the authors. US Government Authors: If the Author(s) are or were officers or employees of the US Government at the time the Work was prepared and the Work was prepared as part of their official duties, the signing Author represents that the Work is not subject to US copyright protection.
- On behalf of all authors of this abstract, and to the best of my knowledge, I affirm that all information in this abstract is reported as accurately as possible.
- I understand that the AAAAI has a policy on the discussion of unlabeled uses of FDA-regulated products. This policy requires me to disclose to the audience at the time of presentation any references to such unlabeled uses. I agree to do so in any presentation resulting from the submission of this abstract.
- I affirm that I have read and understood the Abstract Guidelines document.